In fact, two compounds identified by the biomarker as NRF2 suppressors, the PI3K inhibitor LY294002 and the EGFR erlotinib, did so in the context of cells harboring oncogenic mutations that led to constitutive activation of PI3K in MCF10A cells [54] or lung cancer cells expressing a constitutively active EGFR [55]. This evidence concerns the gene NFE2L2 and lung cancer.